Literature DB >> 20002670

Lymph node mapping in patients with bladder cancer undergoing radical cystectomy and lymph node dissection to the level of the inferior mesenteric artery.

Jørgen B Jensen1, Benedicte P Ulhøi, Klaus M-E Jensen.   

Abstract

OBJECTIVE: To evaluate extended lymph node dissection (LND) as a nodal staging tool in the treatment of invasive carcinoma of the urinary bladder and to suggest a reasonable proximal limit of the dissection. PATIENTS AND METHODS: In all, 170 patients underwent radical cystectomy with extended LND up to the level of the inferior mesenteric artery. Specimens were evaluated as 13 separate packages from pre-designated anatomical locations. The number of LNs and presence of positive LNs (LN+) at each location was prospectively registered.
RESULTS: The median (range) number of LNs removed was 24 (6-62). In all, 25.3% of the patients had LN+. The median (range) number of LN+ was 2 (1-20). Advanced T-stage was correlated with a higher risk of LN+ but not to the specific location of the LN+. Two patients had LN+ above the common iliac bifurcation with no LN+ more distally located within the pelvic region. All other patients with LN+ above the common iliac bifurcation had more distally located LN+. There were no skip lesions to LNs above the aortic bifurcation.
CONCLUSIONS: Extended LND above the common iliac bifurcation including the presacral area provides a more accurate LN staging compared with a standard pelvic LND. Extending the limits above the aortic bifurcation is not necessary from a staging perspective.

Entities:  

Mesh:

Year:  2009        PMID: 20002670     DOI: 10.1111/j.1464-410X.2009.09118.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  8 in total

1.  Lymph node metastasis mapping in extended lymphadenectomy to the level of the inferior mesenteric artery for bladder cancer.

Authors:  Hiroshi Kitamura; Fumiyasu Takei; Sachiyo Nishida; Takashi Muranaka; Naoya Masumori; Taiji Tsukamoto
Journal:  Int J Clin Oncol       Date:  2011-05-25       Impact factor: 3.402

Review 2.  Role of lymph node dissection in management of bladder cancer.

Authors:  Hiroshi Kitamura; Naoya Masumori; Taiji Tsukamoto
Journal:  Int J Clin Oncol       Date:  2011-04-28       Impact factor: 3.402

3.  Role of pelvic lymphadenectomy in the treatment of bladder cancer: a mini review.

Authors:  Ja Hyeon Ku
Journal:  Korean J Urol       Date:  2010-06-21

4.  Does skip metastasis or other lymph node parameters have additional effects on survival of patients undergoing radical cystectomy for bladder cancer?

Authors:  Ozgur Ugurlu; Sumer Baltaci; Guven Aslan; Cavit Can; Cag Cal; Atilla Elhan; Levent Turkeri; Aydin Mungan
Journal:  Korean J Urol       Date:  2015-04-28

5.  Upregulation of Arp2 expression is associated with the prognosis and prediction of lymph node metastasis in bladder urothelial carcinoma.

Authors:  Ning Xu; Gen-Yi Qu; Yu-Peng Wu; Xiao-Dong Li; Min-Yi Lin; Shao-Hao Chen; Xue-Yi Xue; Yong Wei
Journal:  Cancer Manag Res       Date:  2018-03-19       Impact factor: 3.989

6.  The impact of perivesical lymph node metastasis on clinical outcomes of bladder cancer patients undergoing radical cystectomy.

Authors:  Meenal Sharma; Takuro Goto; Zhiming Yang; Hiroshi Miyamoto
Journal:  BMC Urol       Date:  2019-08-16       Impact factor: 2.264

7.  Association of super-extended lymphadenectomy at radical cystectomy with perioperative complications and re-hospitalization.

Authors:  David D'Andrea; Mohammad Abufaraj; Francesco Soria; Kilian Gust; Andrea Haitel; Pierre I Krakiewicz; Shahrokh F Shariat
Journal:  World J Urol       Date:  2019-04-20       Impact factor: 4.226

8.  Extended versus non-extended lymphadenectomy during radical cystectomy for patients with bladder cancer: a meta-analysis of the effect on long-term and short-term outcomes.

Authors:  Yu-Chen Wang; Jie Wu; Bo Dai; Yi-Jun Shen; Chun-Guang Ma; Ding-Wei Ye; Yi-Ping Zhu
Journal:  World J Surg Oncol       Date:  2019-12-21       Impact factor: 2.754

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.